Trials Today

Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

Purpose

A randomized study to determine safety and efficacy of single subcutaneous (SC) administration of HAL treatment in patients with CINP.

Condition

Chemotherapy Induced Neuropathic Pain

Eligibility

Eligible Ages: Over 18 Years
Eligible Sex: All
Accepts Healthy Volunteers: No

Inclusion Criteria

Male or female patients aged ≥18 years. - Neuropathic pain has been present and is attributed to platinum and/or taxane chemotherapy. - Patient has received a cancer chemotherapy regimen that included taxanes and/or platinum and has no active or discernible disease progression.

Exclusion Criteria

Current neuropathic pain with symptoms similar to CINP but attributed to causes other than platinum or taxane chemotherapy. - Patients who have received HAL at any time prior to screening.

Study Design

Phase: Phase 2
Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Masking: Triple (Participant, Care Provider, Investigator)

Arm Groups

Arm	Description	Assigned Intervention
Placebo Comparator Placebo	Placebo	Drug: Placebo Placebo for Subcutaneous Injection
Experimental Halneuron	Halneuron	Drug: Halneuron Halneuron for Subcutaneous Injection

Recruiting Locations

Central Recruiting Site
Sheffield 4089536, Alabama 4829764 35660

Central Recruiting Site
Glendale 5295985, Arizona 5551752 85308

Central Recruiting Site
Fair Oaks 5347287, California 5332921 95628

Central Recruiting Site
Fountain Valley 5350207, California 5332921 92708

Central Recruiting Site
Los Angeles 5368361, California 5332921 91307

Central Recruiting Site
Santa Rosa 5393287, California 5332921 95403

Central Recruiting Site
Wheat Ridge 5443948, Colorado 5417618 80033

Central Recruiting Site
Jacksonville 4160021, Florida 4155751 32205

Central Recruiting Site
Jacksonville 4160021, Florida 4155751 32256

Central Recruiting Site
Lakeland 4161438, Florida 4155751 33812

Central Recruiting Site
Orlando 4167147, Florida 4155751 32832

Central Recruiting Site
Port Charlotte 4169130, Florida 4155751 33952

Central Recruiting Site
Tampa 4174757, Florida 4155751 33613

Central Recruiting Site
Atlanta 4180439, Georgia 4197000 30331

Central Recruiting Site
Gurnee 4894861, Illinois 4896861 60031

Central Recruiting Site
Farmington 4992519, Michigan 5001836 48334

Central Recruiting Site
Fenton 4386381, Missouri 4398678 63026

Central Recruiting Site
Kansas City 4393217, Missouri 4398678 64111

Central Recruiting Site
Las Vegas 5506956, Nevada 5509151 89109

Central Recruiting Site
Garden City 5118226, New York 5128638 11530

Central Recruiting Site
Williamsville 5144588, New York 5128638 14221

Central Recruiting Site
Winston-Salem 4499612, North Carolina 4482348 27103

Central Recruiting Site
Salt Lake City 5780993, Utah 5549030 84107

Central Recruiting Site
Madison 5261457, Wisconsin 5279468 53715

More Details

NCT ID: NCT06848348
Status: Recruiting
Sponsor: Dogwood Therapeutics Inc.

Study Contact

Dogwood Therapeutics
866-620-9255
Mehran@dwtx.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.